Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for ABT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for ABT and 80,000+ other tickers.
See exactly how ABT's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ABT and 80,000+ other tickers.
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm…
Abbott Laboratories maintains a highly diversified healthcare business spanning medical technology, diagnostics, and nutrition. UnitedHealth Group dominates the insurance and healthcare services landscape through its massive scale and integrated Optum division.
I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data points per stock, highlight 12 undervalued and 18 fairly valued Aristocrats, with 39 currently overvalued. Investment candidates vary by style: ADP, BRO, and NDSN for growth; NEE for total return; PEP and O for income; CAT and GWW for past performance.
Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing 1 Building on its leadership in colorectal cancer screening with the Cologuard ® test, Abbott is connecting innovations across the cancer care continuum, from early detection to post-treatment monitoring ABBOTT PARK, Ill., Oct. 23, 2026 /PRNewswire/ -- For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease remain.
Abbott plans to spin off its $8.5B Nutrition business by 2027 while cutting its 2026 sales growth outlook amid diabetes pricing and electrophysiology challenges.